Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Antiva Biosciences, a US-based developer of treatments for human papillomavirus spun out of University of California, San Diego, has secured $31m in a series D round backed by Osage University Partners. The round included internet and technology group Alphabet and pharmaceutical firms EMS and Dong-A, the first two through GV and Brace Pharma Capital respectively. The round was led by Adjuvant Capital and also featured Alexandria Venture Investments, HBM Healthcare Investments, Avestria Ventures, Gaingels, Mana Ventures, Canaan Partners, Sofinnova Ventures,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?